Pete Pharma secures exclusive North American distribution deal with Fagron for M3DIMAKER 3D printing platform

Pete Pharma, a US-based pharmaceutical innovation firm, has entered into an exclusive distribution and commercialization agreement with Fagron to expand its 3D printed medication footprint across the United States and Canada. Under the terms of the agreement, Fagron becomes the sole distributor for Pete Pharma's FABRx ecosystem, which includes the M3DIMAKER hardware, proprietary software, and specialized drug delivery devices. The partnership, announced in April 2026, targets both 503A compounding pharmacies for individual patient prescriptions and 503B outsourcing facilities for large-scale hospital and clinic production. Key leadership involved in the deal includes Pete Pharma co-founder Marc Joiner and Fagron North America Vice President of Sales Andrew Allan.

This move addresses a critical gap in the personalized medicine market by transitioning 3D printing from a research tool to a scalable pharmacy production asset. While competitors like CurifyLabs have focused on specific niche applications, Pete Pharma's FABRx platform offers a comprehensive vertical stack—hardware, software, and quality control—capable of producing diverse dosage forms including immediate-release, sustained-release, oral films, chewables, and suppositories. By leveraging Fagron's established global network spanning 29 countries, Pete Pharma bypasses the traditional barriers to entry for specialized medical hardware, positioning its M3DIMAKER technology directly within the existing pharmaceutical supply chain for customized solid dosage forms.

For the technology to achieve meaningful market penetration, Pete Pharma must now focus on the seamless integration of the M3DIMAKER into high-volume 503B workflows where regulatory compliance and batch traceability are non-negotiable. The success of this expansion depends on the ability of Fagron's sales force to demonstrate the cost-efficiency of automated small-batch production compared to traditional manual compounding. Pharmacy operators should evaluate the platform's ability to meet specific regional regulatory standards for drug manufacturing as the hardware moves from controlled environments into broader commercial pharmacy settings.